Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Axsome Therapeutics (AXSM)

Axsome Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AXSM
DateTimeSourceHeadlineSymbolCompany
11/06/202421:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
11/06/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AXSMAxsome Therapeutics Inc
05/06/202412:38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AXSMAxsome Therapeutics Inc
05/06/202412:35GlobeNewswire Inc.Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem LaboratoriesNASDAQ:AXSMAxsome Therapeutics Inc
04/06/202412:00GlobeNewswire Inc.Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness MonthNASDAQ:AXSMAxsome Therapeutics Inc
03/06/202412:00GlobeNewswire Inc.Axsome Therapeutics Supports Alzheimer’s & Brain Awareness MonthNASDAQ:AXSMAxsome Therapeutics Inc
30/05/202412:00GlobeNewswire Inc.Axsome Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:AXSMAxsome Therapeutics Inc
30/05/202401:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
30/05/202401:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
29/05/202421:24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
29/05/202421:23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
29/05/202412:00GlobeNewswire Inc.Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024NASDAQ:AXSMAxsome Therapeutics Inc
28/05/202421:28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
28/05/202412:00GlobeNewswire Inc.Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) MeetingNASDAQ:AXSMAxsome Therapeutics Inc
08/05/202412:00GlobeNewswire Inc.Axsome Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:AXSMAxsome Therapeutics Inc
06/05/202422:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AXSMAxsome Therapeutics Inc
06/05/202413:09IH Market NewsIndex Futures Point to Strong Monday Opening, Building on Last Week’s Gains; Oil Prices RiseNASDAQ:AXSMAxsome Therapeutics Inc
06/05/202412:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AXSMAxsome Therapeutics Inc
06/05/202412:00GlobeNewswire Inc.Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AXSMAxsome Therapeutics Inc
01/05/202412:00GlobeNewswire Inc.Axsome Therapeutics Recognizes May as Mental Health Awareness MonthNASDAQ:AXSMAxsome Therapeutics Inc
15/04/202412:00GlobeNewswire Inc.Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual MeetingNASDAQ:AXSMAxsome Therapeutics Inc
10/04/202412:00GlobeNewswire Inc.Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6NASDAQ:AXSMAxsome Therapeutics Inc
01/04/202412:00GlobeNewswire Inc.Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating DisorderNASDAQ:AXSMAxsome Therapeutics Inc
25/03/202411:00GlobeNewswire Inc.Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 PatientsNASDAQ:AXSMAxsome Therapeutics Inc
25/03/202410:30GlobeNewswire Inc.Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in NarcolepsyNASDAQ:AXSMAxsome Therapeutics Inc
19/03/202411:00GlobeNewswire Inc.Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive DisorderNASDAQ:AXSMAxsome Therapeutics Inc
05/03/202412:00GlobeNewswire Inc.Axsome Therapeutics to Present at the Leerink Partners Global Biopharma ConferenceNASDAQ:AXSMAxsome Therapeutics Inc
29/02/202423:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
29/02/202423:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
29/02/202422:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AXSM

Your Recent History

Delayed Upgrade Clock